Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis

May 3, 2014 updated by: Bert Op't Eijnde

Rehabilitation in MS: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis

The purpose of this study is to investigate the effects of a combined training programme and a high intensity interval training programme on insulin resistance, muscle strength/ muscle contractile properties, aerobic capacity and body composition in MS patients.

It is assumed that the the above mentioned clinical parameters will improve due to physical exercise.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Diepenbeek, Belgium, 3590
        • REVAL

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosed MS according to the McDonald criteria
  • Expanded Disability Status Scale (EDSS) between 0.5 and 6
  • Be able to train 5 times in 2 weeks at the University

Exclusion Criteria:

  • Comorbidities like cardiovascular-, respiratory-, orthopaedic or metabolic diseases (like diabetes type 2)
  • Having had an relapse in a period of 3 months prior to the start of the intervention period
  • Having an relapse during the intervention period
  • Pregnancy and other contra indications for physical activity
  • Mental disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Combined exercise
12 weeks combined exercise programme (supervised)
Other Names:
  • 12 weeks of high intensity interval training or combined exercise
Experimental: High intensity interval training
12 weeks high intensity interval exercise programme (supervised)
Other Names:
  • 12 weeks of high intensity interval training or combined exercise
No Intervention: Control
sedentary/habitual lifestyle

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
insulin sensitivity (insulin profile)
Time Frame: change from baseline to 12 weeks
glucose and insulin concentration measurements in blood
change from baseline to 12 weeks
muscle contractile properties
Time Frame: from baseline to 12 weeks
measurements of cross sectional area and fiber distribution in muscle fibers of the m. vastus lateralis + measurements of enzymatic reactions, ATP, glycogen, ...
from baseline to 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
muscle strength of knee extensor/flexor
Time Frame: change from baseline to 12 weeks
by means of an isokinetic dynamometer the muscle strength and endurance will be measured
change from baseline to 12 weeks
aerobic capacity
Time Frame: change from baseline to 12 weeks
by means of a submaximal endurance test (ergometer)
change from baseline to 12 weeks
cytokine profile
Time Frame: change from baseline to 12 weeks
measurements of blood cytokine levels
change from baseline to 12 weeks
Self-reported measures
Time Frame: Change from baseline to 12 weeks
The self-reported measures contains some questionnaires
Change from baseline to 12 weeks
body composition
Time Frame: Change from baseline to 12 weeks
Weight, body fat% and lean tissue% will be assessed by means of a DEXA scan
Change from baseline to 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Inez Wens, M.Sc., Reval/Biomed, Hasselt University
  • Study Chair: Bert Opt Eijnde, Ph.D, Reval/Biomed, Hasselt University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2013

Primary Completion (Actual)

March 1, 2014

Study Completion (Actual)

March 1, 2014

Study Registration Dates

First Submitted

April 30, 2013

First Submitted That Met QC Criteria

April 30, 2013

First Posted (Estimate)

May 3, 2013

Study Record Updates

Last Update Posted (Estimate)

May 6, 2014

Last Update Submitted That Met QC Criteria

May 3, 2014

Last Verified

May 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on Training

Subscribe